These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 26006068)

  • 1. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer.
    Song IH; Heo SH; Bang WS; Park HS; Park IA; Kim YA; Park SY; Roh J; Gong G; Lee HJ
    Cancer Res Treat; 2017 Apr; 49(2):399-407. PubMed ID: 27488875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
    Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
    Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
    Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
    Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
    Denkert C; von Minckwitz G; Brase JC; Sinn BV; Gade S; Kronenwett R; Pfitzner BM; Salat C; Loi S; Schmitt WD; Schem C; Fisch K; Darb-Esfahani S; Mehta K; Sotiriou C; Wienert S; Klare P; André F; Klauschen F; Blohmer JU; Krappmann K; Schmidt M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Untch M; Loibl S
    J Clin Oncol; 2015 Mar; 33(9):983-91. PubMed ID: 25534375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ; Salgado R; Dieci MV; Vingiani A; Curigliano G; Gould RE; Castaneda C; D'Alfonso T; Sanchez J; Cheng E; Andreopoulou E; Castillo M; Adams S; Demaria S; Symmans WF; Michiels S; Loi S
    Ann Oncol; 2019 Feb; 30(2):236-242. PubMed ID: 30590484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.
    Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N
    Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
    Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy.
    Jongen L; Floris G; Wildiers H; Claessens F; Richard F; Laenen A; Desmedt C; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; Neven P
    Breast Cancer Res Treat; 2019 Aug; 176(3):699-708. PubMed ID: 31106385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.